Type I interferons in health and disease: molecular aspects and clinical implications
Physiological Reviews · 01.10.2025 · 105 (4) · 2537-2587
DOI: 10.1152/physrev.00047.2024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Physiological Reviews, erschienen am 01.10.2025. Verfasst von Clio P Mavragani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Interferon Type I. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 511 Literaturangaben. Gefördert von: Mary K. Crow , Chair in Autoimmunity and Inflammation Research, Research Grant from Spunk Fund, Inc., Research Contract with Gilead Sciences.
Abstract (Originalsprache)
Type I interferons (IFNs), particularly IFNα and IFNβ, play a crucial role in the human immune response against viral infections. This review delves into the multifaceted antiviral, immunomodulatory, and antitumor physiological roles of type I IFNs, while describing their contribution to the pathogenesis of various disease pathologies including cancer, systemic and organ-specific autoimmunity, neuroinflammation, and atherosclerosis. Genetic determinants influencing activation of type I IFN pathways and therapeutic interventions either targeting or stimulating these pathways in the context of autoimmunity and cancer, respectively, are also discussed. Ultimately, the current understanding of the role of type I IFNs as biomarkers indicative of distinct clinical and serological phenotypes, their correlation with disease activity, their predictive role in therapeutic outcomes across diverse clinical scenarios, as well as the challenges associated with their implementation in clinical practice, are thoroughly addressed. Together, these insights underscore the significant potential of type I IFNs, as mediators and therapeutic targets, to reshape clinical decision-making, while highlighting the urgent need for robust, standardized methodologies for assessment of type I IFNs and their integration into routine practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- Mary Kirkland Center for Lupus Research, Hospital for Special Surgery and Weill Cornell Medicine, New York, New York, United States.
ORCID-Profile: Mary K Crow
Förderung
- Mary K. Crow , Chair in Autoimmunity and Inflammation Research
- Research Grant from Spunk Fund, Inc.
- Research Contract with Gilead Sciences
- Mary K. Crow, Chair in Autoimmunity and Inflammation Research
Zitieren
APA
Mavragani, C. P., & Crow, M. K. (2025). Type I interferons in health and disease: molecular aspects and clinical implications. Physiological Reviews, 105(4), 2537-2587. https://doi.org/10.1152/physrev.00047.2024
Vancouver
Mavragani CP, Crow MK. Type I interferons in health and disease: molecular aspects and clinical implications. Physiological Reviews. 2025;105(4):2537-2587. doi:10.1152/physrev.00047.2024
BibTeX
@article{Mavragani2025,
author = {Mavragani, Clio P and Crow, Mary K},
title = {Type I interferons in health and disease: molecular aspects and clinical implications},
journal = {Physiological Reviews},
year = {2025},
volume = {105},
number = {4},
pages = {2537--2587},
doi = {10.1152/physrev.00047.2024}
}
EUVIMED